Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Full-length human E6-AP:GST fusion protein.|
|Storage buffer||whole serum diluted in PBS|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||Assay dependent|
|Western Blot (WB)||1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunoprecipitation (IP)||See 1 publications below|
PA3-843 detects Angelman Syndrome-Associated protein (E6-AP) from human tissues.
PA3-843 has been successfully used in Western blot and immunoprecipitation procedures. By Western blot, this antibody detects a single ~100 kDa protein representing E6-AP from HeLa cell lysate.
IMPORTANT: E6-AP is a very labile protein. Freeze/thaw cycling of samples results in E6-AP degradation which is observed as a prominent 50 kDa band seen in Western blots.
PA3-843 antigen is bacterially expressed, full-length human E6-AP.
Angelman Syndrome (AS) is a neurological disorder characterized by severe mental retardation, seizures and speech impairment, which results from the lack of a functional maternal copy of the E6-AP gene. E6-AP, or Angelman Syndrome-Associated protein, has been shown to interact with the progesterone receptor as a coactivator, enhancing the transcriptional activity of this steroid receptor. Interestingly, E6-AP (UBE3A) is also a member of the E3 ubiquitin-protein ligase family which plays a role in defining the substrate specificity of the ubiquitin-proteasome degradation system. For example, E6-AP can interact directly with the growth and tumor-suppressive protein, p53 or indirectly as part of a human papillomavirus type 16 or 18 E6 protein complex. This interaction promotes the degradation of p53 via the ubiquitin-proteosome pathway.
These two functions of E6-AP, coactivation and degradation, are independent of one another. Furthermore, the coactivation function of E6-AP in AS patients remains intact and the ubiquitin-protease function of the protein was compromised. It is unclear, however, how this causes AS.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression.
PA3-843 was used in immunoprecipitation to investigate the role of ubiquitination for PSD-95 degradation and AMPA receptor surface expression
|Colledge M,Snyder EM,Crozier RA,Soderling JA,Jin Y,Langeberg LK,Lu H,Bear MF,Scott JD||Neuron (40:595)||2003|
Angelman Syndrome-Associated protein; CTCL tumor antigen se37-2; E6AP ubiquitin-protein ligase; human papilloma virus E6-associated protein; human papillomavirus E6-associated protein; oncogenic protein-associated protein E6-AP; renal carcinoma antigen NY-REN-54; UBE3A
ANCR; AS; E6-AP; E6AP; EPVE6AP; HPVE6A; UBE3A